Our next work would be to interrogate tumor gene expression datasets of NSCLC patients undergoing anti-PD-1 treatment to observe whether CD69 expression level correlates with clinical response rate, or resistance to therapy prior to or at different stages of treatment, and further explain the relevant mechanism. This evidence concerns the gene PDCD1 and neoplasm.